HAELO: a Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants with Hereditary Angioedema (HAE)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

22 Jan 2025 According to an Intellia Therapeutics, the first patient has been dosed at USA location. And, expects to complete enrollment in the second half of 2025 and submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027.
09 Jan 2025 According to an Intellia Therapeutics, first patient to be dosed in 1Q25 and completed enrollment in 2H 2025.
19 Dec 2024 Planned initiation date changed from 1 Oct 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com